本文關(guān)鍵詞： 子宮內(nèi)膜腺癌 ER PR Ki-67 ING4 免疫組織化學(xué)　出處：《石河子大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:檢測(cè)ING4、ER、PR、Ki-67在不同子宮內(nèi)膜組織中的表達(dá),分析其與子宮內(nèi)膜腺癌臨床特征及預(yù)后的關(guān)系,探討在子宮內(nèi)膜腺癌發(fā)生、發(fā)展過程中的意義,為子宮內(nèi)膜腺癌的早期診斷、臨床治療方案的選擇提供理論依據(jù)。方法:回顧性分析2008年1月-2013年1月在石河子大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院婦科行手術(shù)治療并有病理診斷的子宮內(nèi)膜腺癌患者的組織蠟塊,根據(jù)術(shù)后病理診斷進(jìn)行分組,其中對(duì)照組為非瘤子宮內(nèi)膜組織,共20例,病例組為非典型增生子宮內(nèi)膜組織39例及子宮內(nèi)膜腺癌組織76例。分別分析ING4、ER、PR、Ki-67的表達(dá)水平與子宮內(nèi)膜腺癌臨床特征之間的關(guān)系,對(duì)其生存率進(jìn)行回訪,并分析各蛋白在子宮內(nèi)膜腺癌中表達(dá)的相關(guān)關(guān)系。采用SPSS 21.0進(jìn)行統(tǒng)計(jì)分析。結(jié)果:1.子宮內(nèi)膜腺癌組織ER表達(dá)陽性率為48.7%(37/76),低于不典型增生型子宮內(nèi)膜組織76.3%(29/38)和非瘤子宮內(nèi)膜組織95.0%(19/20),在不同組織學(xué)分級(jí)、病理分型、臨床分期的子宮內(nèi)膜腺癌患者組織中ER的表達(dá)差異有統(tǒng)計(jì)學(xué)意義(P0.05)。ER陽性者的生存率明顯高于ER表達(dá)陰性的患者,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。2.PR在子宮內(nèi)膜腺癌組織中陽性率為53.9%(41/76),低于不典型增生型子宮內(nèi)膜組織71.1%(27/38)和非瘤子宮內(nèi)膜組織90.0%(18/20),在不同組織學(xué)分級(jí)、病理分型、臨床分期、腫瘤大小、腫瘤肌層浸潤(rùn)深度的子宮內(nèi)膜腺癌患者組織中PR的表達(dá)差異有統(tǒng)計(jì)學(xué)意義(P0.05)。PR陽性者的生存率明顯高于PR陰性者,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。3.Ki-67在子宮內(nèi)膜腺癌組織中陽性表達(dá)率為69.7%(53/76),高于不典型增生型子宮內(nèi)膜組織34.2%(13/38)和非瘤子宮內(nèi)膜組織10.0%(2/20),在不同組織學(xué)分級(jí)、臨床分期的子宮內(nèi)膜腺癌患者組織中Ki-67的表達(dá)差異有統(tǒng)計(jì)學(xué)意義(P0.05)。Ki-67陽性者的生存率與Ki-67陰性者無明顯差異,差異沒有統(tǒng)計(jì)學(xué)意義(P0.05)。4.子宮內(nèi)膜腺癌組織ING4表達(dá)陽性率為55.3%(42/76),低于不典型增生型子宮內(nèi)膜組織89.5%(34/38)和非瘤子宮內(nèi)膜組織100%(20/20),ING4蛋白在不同組織學(xué)分級(jí)、病理分型、臨床分期的子宮內(nèi)膜腺癌組織中的表達(dá)差異有統(tǒng)計(jì)學(xué)意義(P0.05)。ING4陽性者的生存率與ING4陰性者無明顯差異,差異沒有統(tǒng)計(jì)學(xué)意義(P0.05)。5.子宮內(nèi)膜腺癌組織中ER與PR的表達(dá)呈正相關(guān)(r=0.425,P=0.000),ER與ING4的表達(dá)呈正相關(guān)(r=0.241,P=0.036)。結(jié)論:1.ER、PR及ING4在子宮內(nèi)膜腺癌組織中呈低表達(dá);而Ki-67在子宮內(nèi)膜腺癌組織中高表達(dá),表明四者的表達(dá)均參與了子宮內(nèi)膜腺癌的發(fā)生、發(fā)展過程。2.ER、PR、Ki-67及ING4在子宮內(nèi)膜腺癌的表達(dá)在一定程度上反映出腫瘤的進(jìn)展及惡性程度,對(duì)腫瘤的臨床診斷及治療方案的選擇可以起到一定程度的指導(dǎo)作用。3.ER、PR與子宮內(nèi)膜腺癌的生存率呈顯著相關(guān)。
[Abstract]:Objective: to detect the expression of PRKI-67 in different endometrial tissues, analyze its relationship with the clinical features and prognosis of endometrial adenocarcinoma, and explore its significance in the occurrence and development of endometrial adenocarcinoma, which is the early diagnosis of endometrial adenocarcinoma. Methods: from January 2008 to January 2013, the tissue wax masses of patients with endometrial adenocarcinoma who underwent surgical treatment and pathological diagnosis in the first affiliated Hospital of Shihezi University Medical College were retrospectively analyzed. According to the postoperative pathological diagnosis, 20 cases were divided into two groups: the control group (n = 20) was nontumorous endometrial tissue. There were 39 cases of atypical hyperplasia endometrium and 76 cases of endometrial adenocarcinoma. The relationship between the expression of PRKi-67 and clinical characteristics of endometrial adenocarcinoma was analyzed, and the survival rate was reviewed. The positive rate of ER expression in endometrial adenocarcinoma was 48.7 / 37 / 76, which was lower than that in atypical hyperplasia endometrial tissue (76.33 / 29 / 38) and non-neoplastic endometrial tissue (P < 0.01). The endometrial tissue, 95.0 / 20, is graded in different histology. The difference of ER expression in patients with endometrial adenocarcinoma was statistically significant. The survival rate of patients with positive P0.05 or ER was significantly higher than that of patients with negative expression of ER. The difference was statistically significant in the positive rate of P0.05, PR in endometrial adenocarcinoma tissues was 53.9%, which was lower than that in atypical hyperplasia endometrial tissues (71.1% 27 / 38) and non-tumorous endometrial tissues (90.018% 20%), and in different histological grades, pathological types, clinical stages, tumor size. There was significant difference in the expression of PR in endometrial adenocarcinoma with the depth of myometrial invasion. The survival rate of patients with positive P0.05 or PR was significantly higher than that of patients with negative PR. The positive expression rate of Ki-67 in endometrial adenocarcinoma was 69.7%, which was higher than that in atypical hyperplasia endometrial tissue (34.2x 13 / 38) and non-neoplastic endometrial tissue (10.0% / 20%), and was graded in different histological grades. There was no significant difference in the expression of Ki-67 between the patients with positive P0.05 and Ki-67 and those with negative Ki-67. The positive rate of ING4 expression in endometrial adenocarcinoma was 55.3%, which was lower than that in atypical hyperplasia endometrial tissue (89.55 / 34 / 38) and non-neoplastic endometrial tissue (100% 20 / 20% 20 / 20% ING4) in different histological grade and pathological type. The positive rate of ING4 expression in endometrial adenocarcinoma was 55.3%, which was significantly lower than that in atypical hyperplasia endometrial tissue (89.55 / 34 / 38) and non-neoplastic endometrial tissue (100% 20% 20% ING4). There was no significant difference in the survival rate between the patients with positive P0.05N. ING4 and those with negative ING4 in clinical staging of endometrial adenocarcinoma. There was no significant difference in the expression of ER and PR in endometrial adenocarcinoma tissues. There was a positive correlation between ER and PR expression in endometrial adenocarcinoma tissues. There was a positive correlation between ER and ING4 expression in endometrial adenocarcinoma tissues. Conclusion: 1. The expression of PR and ING4 in endometrial adenocarcinoma tissues is low, while Ki-67 is highly expressed in endometrial adenocarcinoma tissues. The expression of PRKI-67 and ING4 in endometrial adenocarcinoma reflects to some extent the progression and malignancy of endometrial adenocarcinoma. The selection of clinical diagnosis and treatment of tumor may play a guiding role to some extent. 3. ERP has a significant correlation with the survival rate of endometrial adenocarcinoma.
【學(xué)位授予單位】：石河子大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 代魏魏;唐麗萍;盧文;;ING4基因的抗腫瘤作用研究進(jìn)展[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年17期

2 樊子雙;孟杰;貝雪艷;盧思英;付志華;;Ki-67蛋白在大腸癌中的研究進(jìn)展[J];河北醫(yī)學(xué);2016年07期

3 王松;徐德龍;;ERα、ERβ與Ki-67在甲狀腺癌中的研究進(jìn)展[J];河北醫(yī)藥;2016年08期

4 代艷芬;滿霞霞;李佳佳;費(fèi)軍偉;;ER、PR、P53、Ki-67在子宮內(nèi)膜癌組織中的表達(dá)及其臨床意義[J];中國婦幼保健;2016年08期

5 吳乙夫;董曉強(qiáng);楊吉成;盛偉華;魏文祥;;腺病毒載體AdING4對(duì)MCF-7乳腺癌細(xì)胞的增殖抑制及化療增敏作用[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2016年06期

6 李麗;郭東輝;王軼英;ZHENG Wenxin;;子宮內(nèi)膜癌病理研究進(jìn)展及臨床意義[J];實(shí)用婦產(chǎn)科雜志;2015年11期

7 梁艷芳;阮建波;康東平;王玲梅;陳燦;曾今誠;;PTEN缺失型子宮內(nèi)膜癌中ER、PR的表達(dá)及意義[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2015年07期

8 蔡玉潔;邊愛平;趙倩;王春芳;;生長(zhǎng)抑制因子4在子宮內(nèi)膜癌中的表達(dá)及意義[J];中國婦幼保健;2015年15期

9 婁雪玲;周梅玲;張占薪;張喜紅;姚麗;;雌激素受體、孕激素受體、C-erbB-2和Ki-67在子宮內(nèi)膜癌中的表達(dá)及其與臨床病理相關(guān)性[J];中國實(shí)用婦科與產(chǎn)科雜志;2014年07期

10 陶淑芳;蔡靜;李剛強(qiáng);陶雯琪;;STAT3、ER、PR在子宮內(nèi)膜癌中的表達(dá)及意義[J];現(xiàn)代腫瘤醫(yī)學(xué);2014年02期

相關(guān)會(huì)議論文 前1條

1 王晨;孔為民;;子宮內(nèi)膜癌ER、PR及C-erbB-2表達(dá)狀態(tài)與臨床病理特征關(guān)系的研究[A];中華醫(yī)學(xué)會(huì)第十次全國婦產(chǎn)科學(xué)術(shù)會(huì)議婦科腫瘤會(huì)場(chǎng)（婦科腫瘤學(xué)組、婦科病理學(xué)組）論文匯編[C];2012年

相關(guān)博士學(xué)位論文 前1條

1 陳寧;Nrf2參與子宮內(nèi)膜漿液性癌發(fā)病及耐藥機(jī)制的研究[D];山東大學(xué);2011年

相關(guān)碩士學(xué)位論文 前6條

1 黃書煜;膠質(zhì)母細(xì)胞瘤中長(zhǎng)鏈非編碼RNA在單細(xì)胞水平的表達(dá)異質(zhì)性分析[D];大連醫(yī)科大學(xué);2016年

2 曹靜玲;子宮內(nèi)膜癌組織中ER、PR、p53的表達(dá)與血清CA125、臨床病理學(xué)特征及預(yù)后的關(guān)系的研究[D];山東大學(xué);2015年

3 賈亞靜;子宮內(nèi)膜癌、上皮性卵巢癌、早期宮頸癌預(yù)后因素分析[D];河北醫(yī)科大學(xué);2015年

4 侯靜;P53、ER、PR在卵巢漿液性癌與子宮內(nèi)膜樣癌中的表達(dá)及臨床病理學(xué)意義[D];山西醫(yī)科大學(xué);2014年

5 于芷晗;結(jié)直腸癌上皮間質(zhì)轉(zhuǎn)化及其臨床意義的探討[D];大連醫(yī)科大學(xué);2013年

6 郭晨;MCM_2和Ki-67在子宮內(nèi)膜樣腺癌組織中的表達(dá)及意義[D];南昌大學(xué);2011年

，

本文編號(hào)：1553609